Products and innovation

Research activity is focused both on the identification of new hyaluronic acid derivatives with innovative chemical-physical, biological and rheological characteristics and on the definition of synthesis systems with lower environmental impact.

Moreover, at BMG Pharma, preference is given to the use of non-damaging solvents, preferably water for the environment, and reagents that are neither toxic nor harmful.

The synthesis process is designed to totally avoid emissions into the air or environment and allows the recycling of the chemical compounds used.

The therapeutic areas in which our company operates are historically four, namely dermatology, oral health, joints and women's health.

The increase in the ageing population and the incidence of related diseases is driving the company to seek effective solutions for people's new needs.

Antiaging, osteoarticular pathologies, atrophies and tissue injuries are areas of application for our Hyaluromimethic® technology.

Thanks to the chemical-physical properties of the new and exclusive hyaluronic acid derivatives, BMG Pharma is developing an innovative portfolio for aesthetic, dermatological and tissue regeneration applications, opening up new applications that correspond to unresolved "market needs".